INTRODUCTION
Intracranial arterial stenosis (ICAS) is a major cause of ischemic stroke, which may occur even under the best medical management. 23) It is estimated that ICAS causes approximately 5-10% of ischemic strokes in the United States and 33-67% of ischemic strokes in Asia. 26) Recently, a rapid emergence of atherosclerosis in Asia was reported in relation to coronary artery disease, 27) which may additionally be associated with the high prevalence of ICAS-induced stroke.
Several mechanisms have been proposed with re-Regression of asymptomatic intracranial arterial stenosis by aggressive medical management with a lipid-lowering agent Bo Seok Kim, Jun Seob Lim, Jae Uk Jeong, Jong Hyun Mun, Sung Hyun Kim Kwangju Christian Hospital Objective : The incidence rate of stroke as a result of intracranial arterial stenosis (ICAS) is higher in Asian countries than in the West. We aimed to analyze the regression, lack of change, or progression of asymptomatic ICAS after the administration of rosuvastatin and associated factors.
Methods : The patients who had undergone computed tomography angiography (CTA) at our hospital and had been diagnosed with ICAS with no ischemic event in the stenosed vascular territory were included in the study. They were administered 20mg of rosuvastatin per day. After a follow-up period of at least 6 months after treatment, the patients were examined using CTA again and the clinical information and imaging results were analyzed.
Results : In total, 48 patients were diagnosed with asymptomatic ICAS. During the final follow-up examination, it was found that the stenotic lesion regressed in 30 patients, whereas it remained unchanged or progressed without any adverse effects in 18 patients. In univariate analysis, the regressed group showed significantly higher differences in the levels of total cholesterol and low-density lipoprotein (LDL) between their initial and final values (both, p=0.031 for both). In the multivariate analysis, a significantly higher difference in the levels of LDL between its initial and final measurement was seen in the regressed group (p=0.035, odds ratio(OR) 3.9).
Conclusions : Rosuvastatin was found to have better lipid-lowering effects for total cholesterol and particularly LDL in patients whose ICAS had regressed. We concluded that rosuvastatin administration can be recommended for the treatment of patients with asymptomatic ICAS. 14) Aggressive medical management for symptomatic ICAS is assumed to be more effective than percutaneous transluminal angioplasty and stenting. 6) Medical management with the administration of lipid-lowering agents has been recommended by several large studies. 6)8) Although there is no general consensus on the treatment of asymptomatic ICAS, aggressive management seems to be required in such cases as well. However, in spite of the exploration of different treatment options, the prognosis of asymptomatic ICAS has not been thoroughly investigated to date. The prognosis of asymptomatic atherosclerotic stenosis of the middle cerebral artery is reported to follow a benign long-term course with a low risk of ipsilateral stroke in medically-treated Caucasian patients. 15) However, an Asian study has reported that asymptomatic ICAS by itself was an independent risk factor of stroke. 19) Thus far, the association between the regression of ICAS and the administration of lipid-lowering agents has been reported by few studies. However, there have been no studies comparing a regressed ICAS group with a static or progressive group after the administration of rosuvastatin. In this study, we compared patients with regressed ICAS to those with unchanged or progressed ICAS after medical treatment, and investigated the related factors.
MATERIALS AND METHODS

Study design
This study was performed based on a review of the 
Clinical information
A history of diabetes, hypertension, ischemic heart disease, smoking, dyslipidemia, and family history of cerebrovascular events was recorded. Laboratory tests were performed to assess the levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides. All the patients received optimal medical management with aggressive control of the risk factors, including appropriate use of antiplatelet, antihypertensive, and antidiabetic drugs.
Evaluation of stenosis
The degree of stenosis was calculated using the method of the Warfarin-Aspirin Symptomatic Intracranial The level of statistical significance was set at p<0.05. Table 2 ).
RESULTS
Cases
The differences between the groups were not statistically significant; however, the difference between the initial and final follow-up stenosis value was statistically significant between the two groups (p < 0.001, Table 2 ). The representative images of M1 stenosis of a 60-year-old male patient from the regressed group who was administered 20mg/day of rosuvastatin for 46 months are shown in Fig. 1 . In the sta- 
Dyslipidemia analyses
All the described differences between the initial and final measurements were calculated by subtracting the final value from the initial value. Among the variables of dyslipidemia, the differences in total cholesterol (p=0.031) and LDL (p=0.031) between the initial and final measurements were higher in the regressed group than in the stationary/progressed group in the univariate analysis ( Table 3 ). The multivariate analysis of significant variables including Δ total cholesterol and Δ LDL, which showed statistical significance, revealed higher Δ LDL (p=0.035) in the regressed group. The odds ratio was 3.9, which signified that patients with an increased difference between the initial and final LDL values were 3.9 times more likely to be in the regressed group (Table 4) .
DISCUSSION
We conducted this study to evaluate whether asymptomatic ICAS regressed or remained unchanged/ progressed after the administration of rosuvastatin while considering the associated factors of ICAS.
Our major finding was that rosuvastatin had better lipid-lowering effects in terms of total cholesterol and particularly LDL in patients with regressed ICAS. Moreover, 2 patients of the stationary/progressed group developed ischemic events in the stenosed vascular territory, while no such events were observed in the regressed group.
A B C D
Antiplatelet agents aspirin and clopidogrel, which are not known to not have any particular effect on vasodilation, were used for the patients in this study.
Other antiplatelet agents, such as cilostazol, which stabilize endothelial cells and inhibit proliferation of vascular smooth-muscle cells causing vasodilation, were not used. 24) Therefore, the effects of other antiplatelet drugs on the vascular-structure modification may be excluded.
Statins are known to have stabilizing effects on vascular endothelial cells and can be used to slow the progression of and even regress atherosclerosis. 7) The beneficial effect of statins on the regression of carotid intima media thickness has been widely demonstrated. 3 A study on symptomatic ICAS patients who had a history of ischemic events found that sex is a major predictor of ICAS regression. 23) Another study re-ported that asymptomatic ICAS showed a lower rate of progression than symptomatic ICAS. 13) This study also suggested that a low fasting glucose level and the use of angiotensin receptor blockers were associated with a favorable course of asymptomatic ICAS.
In this study, we found that the differences between 
CONCLUSION
We evaluated the factors associated with ICAS regression after the administration of high-dose rosuvastatin. The differences between the initial and final measured values of total cholesterol and LDL were statistically significantly associated with the regression of ICAS. Our findings support the notion that rosuvastatin had better lipid-lowering effects in patients whose stenotic vessels were regressed.
